FAQ · GLP-1 · Editorial commentary

How does the NHS Mounjaro pathway work?

Editorial commentary on published NICE guidance. NICE TA1026 sets the framework for NHS tirzepatide (Mounjaro) access in England, phased across three cohorts between 2025 and 2027. Cohort 1 (BMI 40+, four or more qualifying comorbidities) has been live since June 2025. Cohort 2 is scheduled for June 2026. Cohort 3 is expected in 2027. Ethnicity-adjusted thresholds apply for South Asian, Chinese, Black African, and African-Caribbean populations. Whether an individual qualifies, and when they will be assessed, is a decision for their GP and the local Specialist Weight Management Service. This page summarises the published guidance and does not constitute clinical advice.

Your GP and NHS Specialist Weight Management Service decide eligibility, prescribing, and pathway entry. The notes below are editorial commentary on published NICE and NHS England guidance, not individual clinical advice.

What NICE TA1026 reports

NICE Technology Appraisal TA1026 recommends tirzepatide as an option for managing overweight and obesity in adults within an NHS Specialist Weight Management Service, alongside a reduced calorie diet and increased physical activity. NHS England subsequently announced a phased rollout. The published documents describe how eligibility is calculated (BMI plus qualifying comorbidities, with ethnicity-adjusted thresholds) and who delivers the assessment (the local SWMS, on referral from a GP).

What the published rollout describes

According to NHS England's published rollout, the cohorts step down from highest acuity to lower BMI thresholds over a multi-year window. Cohort 1 began in June 2025. Cohort 2 is scheduled for June 2026. Cohort 3 is expected from 2027. Comorbidities counted under the published guidance include type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, and established cardiovascular disease. The ethnicity-adjusted BMI threshold is 2.5 kg/m² lower for the populations listed in the NICE guidance.

Who decides whether you qualify

Eligibility is a clinical decision made by your GP and confirmed at SWMS assessment. The SWMS multidisciplinary team (typically dietitian, psychologist, prescriber) assesses suitability, prescribes where appropriate, and operates the 12-month structured programme described in TA1026. Wait times between GP referral and SWMS assessment vary materially between Integrated Care Boards.

Where to ask

· Find or contact your NHS GP practice to discuss whether referral to SWMS is appropriate.
· Read NICE TA1026 in full.
· Per-ICB editorial overviews on local rollout commentary.

Private versus NHS routes

Editorial note only. Mounjaro is also available privately in the UK through MHRA-regulated clinics and pharmacies operating to the manufacturer's licensed indication. Whether a private route is appropriate for an individual is a decision between that person and a UK-licensed prescriber. PeptideClear does not prescribe, dispense, or recommend a medication for a specific person.

Decision routing: NHS questions go to your GP. Private questions go to a UK-licensed prescriber. This page is editorial commentary on published guidance.